Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.5.0.2
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Consolidated Statements Of Operations        
Revenues
Operating expenses:        
Amortization & depreciation 44 413
General and administrative 80,768 127,363 275,191 316,594
Total operating expenses 80,768 127,407 275,191 317,007
Loss from operations (80,768) (127,407) (275,191) (317,007)
Other income (expense):        
Gain (Loss) on fair value adjustment - derivatives (86,394) (86,394) 25,456
Gain on debt reversal 108,000 108,485
Interest expense (49,193) (66,964) (167,290) (179,482)
Interest expense - beneficial conversion feature (6,250) (6,250) (17,500)
Total other income (expense) (135,587) 34,786 (259,934) (63,041)
Loss before provision for income taxes (216,355) (92,621) (535,125) (380,048)
Provision for income tax
Net loss before noncontrolling interest (216,355) (92,621) (535,125) (380,048)
Less: Net loss attributable to noncontrolling interest (924) (1,626) (3,047) (3,493)
Net loss attributable to TranBioTec, Inc. $ (215,431) $ (90,995) $ (532,078) $ (376,555)
Net loss per share        
(Basic and fully diluted) $ (0.003) $ (0.002) $ (0.008) $ (0.006)
Weighted average number of common shares outstanding 67,751,068 59,696,720 67,176,250 58,927,503